Novo Nordisk (NYSE: NVO) details progress on DKK 15B share buyback

Rhea-AI Filing Summary

Novo Nordisk A/S provides an update on its ongoing share repurchase programme. The company is running an overall buyback of up to DKK 15 billion over 12 months beginning 4 February 2026, aimed at repurchasing B shares.

Under the specific programme running from 4 February 2026 to 4 May 2026, Novo Nordisk plans to buy back up to DKK 3.8 billion of B shares. As of 27 February 2026, it has repurchased 4,045,000 B shares at an average price of DKK 286.95, for a total of DKK 1,160,693,639.

Following these transactions, Novo Nordisk holds 21,434,799 B shares as treasury shares, representing 0.5% of its share capital. The company’s total share capital consists of 4,465,000,000 A and B shares, including treasury shares.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 

________________

FORM 6-K

________________

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

March 2, 2026

________________

NOVO NORDISK A/S

 (Exact name of Registrant as specified in its charter)

Novo Allé 1

DK- 2880, Bagsvaerd

Denmark

(Address of principal executive offices)

________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒           Form 40-F ☐

 

 

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 2 March 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.

Under the programme initiated 4 February 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 3.8 billion in the period from 4 February 2026 to 4 May 2026.

Since the announcement 23 February 2026, the following transactions have been made:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	2,750,000		841,997,435
23 February 2026	275,000	267.50	73,563,182
24 February 2026	250,000	244.52	61,130,747
25 February 2026	250,000	240.03	60,006,450
26 February 2026	260,000	239.10	62,165,344
27 February 2026	260,000	237.81	61,830,481
Accumulated under the programme	4,045,000		1,160,693,639

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 21,434,799 B shares of DKK 0.10 as treasury shares, corresponding to 0.5% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12month period beginning 4 February 2026. As of 27 February 2026, Novo Nordisk has since 4 February 2026 repurchased a total 4,045,000 B shares at an average share price of DKK 286.95 per B share equal to a transaction value of DKK 1,160,693,639.

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Media:
Ambre James-Brown	Liz Skrbkova (US)
+45 3079 9289	+1 609 917 0632
globalmedia@novonordisk.com	lzsk@novonordisk.com
Investors:
Michael Novod	Jacob Martin Wiborg Rode
+45 3075 6050	+45 3075 5956
nvno@novonordisk.com	jrde@novonordisk.com
Max Ung	Sina Meyer
+45 3077 6414	+45 3079 6656
mxun@novonordisk.com	azey@novonordisk.com
Alex Bruce	Christoffer Sho Togo Tullin
+45 3444 2613	+45 3079 1471
axeu@novonordisk.com	cftu@novonordisk.com
Frederik Taylor Pitter
+1 609 613 0568
fptr@novonordisk.com

Novo Nordisk A/S Investor Relations	Novo Allé 1 2880 Bagsværd Denmark	Telephone: +45 4444 8888	www.novonordisk.com CVR no: 24 25 67 90
			Company announcement No 15/ 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: March 2, 2026   NOVO NORDISK A/S   Maziar Mike Doustdar Chief Executive Officer

FAQ

What share buyback programme did Novo Nordisk (NVO) outline in this report?

Novo Nordisk outlined an overall share repurchase programme of up to DKK 15 billion over a 12-month period beginning 4 February 2026. This framework governs multiple buyback tranches focused on repurchasing B shares in the market.

How large is the current Novo Nordisk (NVO) B-share buyback tranche?

The current tranche targets repurchases of B shares for up to DKK 3.8 billion from 4 February 2026 to 4 May 2026. This tranche operates under EU Safe Harbour Rules as part of the broader DKK 15 billion programme.

How many Novo Nordisk (NVO) B shares have been repurchased so far?

As of 27 February 2026, Novo Nordisk has repurchased 4,045,000 B shares since 4 February 2026. The average purchase price was DKK 286.95 per B share, representing a total transaction value of DKK 1,160,693,639.

What percentage of Novo Nordisk (NVO) share capital is held as treasury shares?

After the reported transactions, Novo Nordisk holds 21,434,799 B shares as treasury shares. This amount corresponds to 0.5% of the company’s total share capital of 4,465,000,000 A and B shares combined.

On which exchanges are Novo Nordisk (NVO) shares listed?

Novo Nordisk’s B shares are listed on Nasdaq Copenhagen under the symbol Novo-B. The company’s American Depositary Receipts (ADRs) are listed on the New York Stock Exchange under the ticker NVO, giving U.S. investors trading access.

Over what period does Novo Nordisk (NVO) plan to execute the DKK 15 billion buyback?

Novo Nordisk expects to repurchase B shares for up to DKK 15 billion during a 12-month period beginning 4 February 2026. Individual tranches, like the current DKK 3.8 billion programme, operate within that overall timeframe.